| CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells K Petri, W Zhang, J Ma, A Schmidts, H Lee, JE Horng, DY Kim, IC Kurt, ... Nature biotechnology 40 (2), 189-193, 2022 | 164 | 2022 |
| PrimeDesign software for rapid and simplified design of prime editing guide RNAs JY Hsu, J Grünewald, R Szalay, J Shih, AV Anzalone, KC Lam, MW Shen, ... Nature Communications 12 (1), 1034, 2021 | 154 | 2021 |
| Engineered CRISPR prime editors with compact, untethered reverse transcriptases J Grünewald, BR Miller, RN Szalay, PK Cabeceiras, CJ Woodilla, ... Nature biotechnology 41 (3), 337-343, 2023 | 55 | 2023 |
| Genome-wide specificity of highly efficient TALENs and CRISPR/Cas9 for T cell receptor modification F Knipping, MJ Osborn, K Petri, J Tolar, H Glimm, C von Kalle, M Schmidt, ... Molecular Therapy Methods & Clinical Development 4, 213-224, 2017 | 47 | 2017 |
| Analysis of off-target effects in CRISPR-based gene drives in the human malaria mosquito WT Garrood, N Kranjc, K Petri, DY Kim, JA Guo, AM Hammond, ... Proceedings of the National Academy of Sciences 118 (22), e2004838117, 2021 | 41 | 2021 |
| A code of ethics for gene drive research GJ Annas, CL Beisel, K Clement, A Crisanti, S Francis, M Galardini, ... The CRISPR journal 4 (1), 19-24, 2021 | 37 | 2021 |
| SHERLOCK and DETECTR open a new frontier in molecular diagnostics K Petri, V Pattanayak The CRISPR journal 1 (3), 209-211, 2018 | 29 | 2018 |
| CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer’s disease PSEN1 M146L mutation E Konstantinidis, A Molisak, F Perrin, L Streubel-Gallasch, S Fayad, ... Molecular therapy-Nucleic acids 28, 450-461, 2022 | 25 | 2022 |
| Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects K Petri, DY Kim, KE Sasaki, MC Canver, X Wang, H Shah, H Lee, ... Biorxiv, 2021.04. 05.438458, 2021 | 23 | 2021 |
| Comparative next-generation sequencing of adeno-associated virus inverted terminal repeats K Petri, R Fronza, R Gabriel, C Käppel, A Nowrouzi, RM Linden, ... Biotechniques 56 (5), 269-273, 2014 | 16 | 2014 |
| Presence of a trs-Like Motif Promotes Rep-Mediated Wild-Type Adeno-Associated Virus Type 2 Integration K Petri, R Gabriel, L Agundez, R Fronza, S Afzal, C Kaeppel, RM Linden, ... Journal of virology 89 (14), 7428-7432, 2015 | 14 | 2015 |
| Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions W Zhang, K Petri, J Ma, H Lee, CL Tsai, JK Joung, JRJ Yeh eLife 12, RP90948, 2024 | 6 | 2024 |
| Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells J Zeng, MA Nguyen, P Liu, L Ferreira da Silva, LY Lin, DG Justus, K Petri, ... BioRxiv, 2023.05. 27.542323, 2023 | 6 | 2023 |
| Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents JK Joung, V Pattanayak, K Petri, KE Sasaki US Patent 11,976,324, 2024 | 3 | 2024 |
| Author correction: CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells K Petri, W Zhang, J Ma, A Schmidts, H Lee, JE Horng, DY Kim, IC Kurt, ... Nature Biotechnology 40 (2), 273-273, 2022 | 2 | 2022 |
| Combined+ 58 and+ 55 BCL11A enhancer editing Yields exceptional efficiency, specificity and HbF induction in human and NHP preclinical models J Zeng, S Demirci, MA Nguyen, LY Lin, SA Maitland, E Mintzer, Y Wu, ... Blood 138, 1852, 2021 | 2 | 2021 |
| Genome-Editing–Gentherapie 2.0 oder nur eine Wunschvorstellung? B Fehse, J Grünewald, K Petri Gen-und Zelltherapie 2.023-Forschung, klinische Anwendung und Gesellschaft …, 2023 | 1 | 2023 |
| Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents JK Joung, V Pattanayak, K Petri US Patent App. 18/402,501, 2024 | | 2024 |
| Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents JK Joung, V Pattanayak, K Petri US Patent 11,898,203, 2024 | | 2024 |
| Highly sensitive in vitro assays to define substrate preferences and sites of nucleic acid cleaving agents JK Joung, V Pattanayak, K Petri US Patent 11,845,987, 2023 | | 2023 |
